{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:12:15Z","timestamp":1788541935084,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00498","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T09:25:43Z","timestamp":1557307543000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System"],"prefix":"10.3389","volume":"10","author":[{"given":"Fl\u00e1via Campos","family":"Barcelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guacira Corr\u00eaa de","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Jorge Sobreira da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabr\u00edcio Alves Barbosa da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisangela da Costa","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14740338.2017.1325463","article-title":"Methods for safety signal detection in healthcare databases: a literature review","volume":"16","author":"Arnaud","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/TCRM.S137144","article-title":"Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs","volume":"13","author":"Arora","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"B3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.111\/jep.12184","article-title":"Pharmacovigilance in oncology: evaluation of current practice and future perspectives","volume":"20","author":"Baldo","year":"2014","journal-title":"J. Eval. Clin. Pract."},{"key":"B4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2146\/ajhp080090","article-title":"Caring for the treatment-experienced breast cancer patient: the phrmacist\u2018s role","volume":"65","author":"Barbour","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1102\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoedidemiol. Drug Saf."},{"key":"B6","unstructured":"Health Ministry. 2018"},{"key":"B7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J. Allerg. Clin. Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3389\/fphar.2018.01010","article-title":"Propensity score-based approaches in high dimension for pharmacovigilance signal detection: an empirical comparison on the French spontaneous reporting database","volume":"9","author":"Courtois","year":"2018","journal-title":"Front Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.critrevonc.2015.04.011","article-title":"Taxane induced-neuropathy in patients affected by breast cancer: Literature review","volume":"96","author":"De Lullis","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.25756\/rpf.v6il.36","article-title":"Medidas de desproporcionalidade na detec\u00e7\u00e3o de sinal em farmacovigil\u00e2ncia","volume":"6","author":"Dias","year":"2014","journal-title":"Rev. Port. Farmacoter."},{"key":"B11","unstructured":"Screening for Adverse Reactions in EudraVigilance2016"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/cncr.30547","article-title":"Treatment-associated toxicities reported by patients with early stage invasive breast cancer","volume":"123","author":"Frise","year":"2017","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz","year":"2012","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"B14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/2042098916685010","article-title":"The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies","volume":"8","author":"Hauben","year":"2017","journal-title":"Ther. Adv. Drug Saf."},{"key":"B15","unstructured":"World Cancer Report 20142014"},{"key":"B16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","article-title":"Breast cancer treatment-induced cardiotoxicity","volume":"16","author":"Martel","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B18","unstructured":"Medical Dictionary for Regulatory Activities2018"},{"key":"B19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and stengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Brit. J. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e00000218","DOI":"10.1590\/0102-311x00000218","article-title":"Evolution and key elements of the Brazilian pharmacovigilance system: a escoping review beginning with the creation of the Brazilian Health Regulatory Agency","volume":"34","author":"Mota","year":"2018","journal-title":"Cad. Sa\u00fade P\u00fabl."},{"key":"B21","unstructured":"Guidelines NCCN Evidence Blocks2017"},{"key":"B22","unstructured":"Sistema de Notifica\u00e7\u00e3o em Vigil\u00e2ncia Sanit\u00e1ria (Notivisa)2018"},{"key":"B23","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.iac.2017.004","article-title":"Management of hypersentivity reactions to taxanes","volume":"37","author":"Picard","year":"2017","journal-title":"Immunol. Allerg. Clin. North Am."},{"key":"B24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12016-014-8416-0","article-title":"Re-visiting hypersensitivity reactions to taxanes: a comprehensive review","volume":"49","author":"Picard","year":"2015","journal-title":"Clin. Rev. Allerg. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/s1470-2015(16)30312-6","article-title":"21st Century pharmacovigilance: efforts, roles and responsabilities","volume":"17","author":"Pitts","year":"2016","journal-title":"Lancet Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/pds.1836","article-title":"Data mining on eletronic health record databases for signal detection in pharmacovigilance: which events to monitor?","volume":"18","author":"Trifir\u00f2","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1586\/17512433.2015.974555","article-title":"Adverse reactions to oncologic drugs: spontaneous reporting and signal detection","volume":"8","author":"Tuccori","year":"2015","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B28","unstructured":"Guidance for industry. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. Rockville, MD2005"},{"key":"B29","unstructured":"Uppsala Monitoring Centre2018"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/s1470-2015(16)30384-9","article-title":"Generic oncology drugs: are they all safe?","volume":"17","author":"Yang","year":"2016","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T09:25:46Z","timestamp":1557307546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,8]]},"references-count":30,"alternative-id":["10.3389\/fphar.2019.00498"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00498","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,8]]},"article-number":"498"}}